Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Year in Review / Wrap-Ups
Year in Review
Year in Review
2023
2022
2021
LBCL 2022 Year in Review
NSCLC IO 2022 Midyear Review
AACR & ASCO 2021 – Midyear Review
Dual IO 2021 Year in Review
Year in Review
Nivolumab with or without Docetaxel for Patients with Previously Treated Advanced or Recurrent NSCLC: Results from the Phase 2/3 TORG1630 Trial
NSCLC IO 2022 - Midyear Review
The combination of nivolumab plus docetaxel for NSCLC in the second-line setting improved overall survival, progression-free survival, and overall response rate, despite a slightly elevated risk of toxicity.
Read More ›
Year in Review
Toripalimab versus Placebo in Combination with First-Line Chemotherapy for Advanced NSCLC without EGFR/ALK Mutations: CHOICE-01 Phase 3 Study
NSCLC IO 2022 - Midyear Review
First-line treatment of patients with advanced NSCLC with toripalimab plus chemotherapy resulted in improved progression-free survival and overall survival compared with chemotherapy alone.
Read More ›
Year in Review
A Phase 3 Study of First-Line Sugemalimab versus Placebo plus Platinum-Based Chemotherapy for Patients with Metastatic NSCLC: GEMSTONE-302
NSCLC IO 2022 - Midyear Review
Sugemalimab plus chemotherapy resulted in statistically significant and clinically meaningful progression-free survival and overall survival improvement compared with placebo plus chemotherapy, regardless of tumor histology or PD-L1 expression level, in patients with newly diagnosed metastatic NSCLC.
Read More ›
Year in Review
First-Line Nivolumab plus Ipilimumab in Combination with Chemotherapy versus Chemotherapy Alone in Patients with Metastatic NSCLC: 3-Year Update from CheckMate 9LA
NSCLC IO 2022 - Midyear Review
The 3-year extended follow-up of CheckMate 9LA demonstrated that first-line nivolumab plus ipilimumab in combination with limited chemotherapy resulted in long-term, durable clinical benefit compared with chemotherapy alone in patients with metastatic NSCLC, regardless of PD-L1 mutation status.
Read More ›
Year in Review
Resistance Biomarkers to PD-1/PD-L1–Targeted Immune Checkpoint Inhibitors: The PIONeeR Trial
NSCLC IO 2022 - Midyear Review
The PIONeeR trial identified 37 biomarkers that could predict resistance to anti–PD-1/PD-L1 therapy before treatment initiation.
Read More ›
Year in Review
First-Line Treatment of Metastatic NSCLC with Durvalumab with or without Tremelimumab in Combination with Chemotherapy: AE Management in the POSEIDON Trial
NSCLC IO 2022 - Midyear Review
The safety profile of durvalumab ± tremelimumab plus chemotherapy was manageable, but with more immune-related adverse events observed with durvalumab and tremelimumab.
Read More ›
Year in Review
Camrelizumab Combined with Apatinib and Albumin Paclitaxel in Advanced Nonsquamous NSCLC: CAPAP-Lung Phase 2 Study
NSCLC IO 2022 - Midyear Review
Camrelizumab plus albumin paclitaxel and apatinib resulted in promising antitumor activity with an acceptable safety profile for first-line treatment of advanced NSCLC.
Read More ›
Year in Review
MEDI5752, a Novel PD-1/CTLA-4 Bispecific Checkpoint Inhibitor for Advanced Solid Tumors: First-in-Human Study
NSCLC IO 2022 - Midyear Review
MEDI5752, a novel PD-1/CTLA-4 bispecific checkpoint inhibitor, showed promising antitumor activity and durable clinical benefit and was tolerated at doses 1500 mg.
Read More ›
Year in Review
Analysis of Serum Protein Levels for Biomarker-Guided Therapy with Nivolumab with or without Ipilimumab in Patients with Squamous-Cell Lung Cancer: The SWOG Lung-MAP S1400I Trial
NSCLC IO 2022 - Midyear Review
Analysis of the changes in blood circulating soluble proteins resulted in identifying potential response biomarkers to immune checkpoint inhibitors in patients with squamous-cell lung cancer.
Read More ›
Year in Review
Phase 2 Study of Nivolumab plus Ipilimumab in Metastatic Uveal Melanoma
Dual IO 2021 - Year in Review
Nivolumab plus ipilimumab demonstrates deep and sustained confirmed responses for patients with metastatic uveal melanoma.
Read More ›
Page 5 of 9
1
2
3
4
5
6
7
8
9
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us